Generic Drug Pricing Strategy: The Complete Playbook for Patent Cliffs, IP Valuation, and Market Entry
The generic drug industry runs on a paradox. Generics fill more than 90% of all U.S. prescriptions yet account for […]
The generic drug industry runs on a paradox. Generics fill more than 90% of all U.S. prescriptions yet account for […]
Branded drugs generating $356 billion in worldwide sales face patent expiration between 2023 and 2028. Every one of those assets
AI Drug Patent Search: The Definitive Guide to Predictive Pharmaceutical IP Intelligence Read Post »
1. Market Scale and Growth Trajectory Sizing the Opportunity The global generic drug market sat between $488 billion and $491
Generic Drug Market: The Complete IP, Regulatory & Investment Playbook Read Post »
Key Takeaways Section 1: The Patent Cliff Reframed: A Market Transformation, Not a Disaster 1.1 The Standard Narrative Gets It
Drug Patent Expiration: The $400 Billion Contrarian Investment Playbook Read Post »
The Drug Price Competition and Patent Term Restoration Act of 1984 — the Hatch-Waxman Act — is the single piece
Generic and biosimilar drugs saved the U.S. healthcare system $445 billion in 2023 alone, accumulating to over $2.9 trillion across
Section 1: The 505(b)(2) Value Proposition — Pricing Incremental Innovation 1.1 Why the Pathway Exists and What It Actually Does
505(b)(2) Pricing & Market Access: The Complete Commercial Playbook Read Post »
Why Standard Patent Intelligence Is Failing You The patent cliff is no longer the right mental model. For two decades,
University Technology Transfer Offices (TTOs) sit at one of the most commercially consequential intersections in American innovation: the point where
Drug Patent Data for University Tech Transfer: The Complete Strategic Playbook Read Post »
Get fresh news and insights, drug patent expirations & more…